Admin
Verse of the Day
The Newsroom
Recent Posts
- Those Wonderful Church Bulletin Bloopers
- Be Careful With Those Pardons Mr. President….Updated
- Living With Caylee
- Malia and Sasha Obama Get The First Look At What Will Be Their Bedrooms At The White House
- Elephants Have Musical Preferences Too
Recent Comments
- Sue on Those Wonderful Church Bulletin Bloopers
- newton on Is Obama the anti-christ? I Don’t Think So
- newton on Is Obama the anti-christ? I Don’t Think So
- ~J~ on Be Careful With Those Pardons Mr. President….Updated
- ~J~ on Is Obama the anti-christ? I Don’t Think So
- Jonathan on Is Obama the anti-christ? I Don’t Think So
- Jonathan on Is Obama the anti-christ? I Don’t Think So
- Jonathan on Is Obama the anti-christ? I Don’t Think So
- Sue on Changes
- ~J~ on No More Bailouts for Auto or Any Other Industry
Blogroll
Newspaper Rack
Categories
Can you believe this? . These are the last people in the world, except for Congress, who deserve a raise .
Written by GussBefore paying $48,823 in cash bonuses to its chief of regulatory affairs in 2005, the Food and Drug Administration asked her to sign a simple declaration: “If I am unable to receive a retention allowance, I am likely to leave the federal government for a higher paying position in the private sector,” wrote Margaret O’K. Glavin.
Glavin’s statement did not detail a specific job offer, but that did not impede the payment. Over the past 4 1/2 years, she has collected more than $178,000 in cash bonuses — on top of her $159,840 annual salary.
FDA officials justified Glavin’s bonuses by saying her pay should be close to the salaries of those employed by companies she regulates, namely Washington lobbyists. The private-sector comparison has prompted large cash bonuses for top agency officials to quadruple since 2002, to $13.6 million in 2005, according to FDA officials and salary information provided to Congress.
The bonuses were paid during a rough patch at the FDA, encompassing a shortage of flu vaccine and embarrassing recalls of the pain-relieving drug Vioxx and malfunctioning heart defibrillators. Throughout, the agency repeatedly insisted that it lacked the resources to conduct adequate food and drug inspections.



